QUALITY OF LIFE OF MALE GOUTY PATIENTS: ARE THERE DIFFERENCES FROM THE POPULATION? RESULTS OF A COMPARATIVE STUDY
https://doi.org/10.14412/1995-4484-2014-300-303
Abstract
Objective: to assess quality of life of male gouty patients with SF-36 questionnaire versus the standardized indicators of population-based control.
Subjects and methods. The study included 153 male patients with gout, in each case the diagnosis was verified by detection of monosodium urate crystals. The patients' mean age was 47.5±12.9 years (25 to 74 years); the median dis- ease duration was 5.6 [3.03; 9.7] years. The SF-36v1 questionnaire was used to compare the quality of life of the patients with the standardized indicators of the Russian population. The comparison was made separately in different age groups: 25–34 years (n=23), 35–44 years (n=48), 45–54 years (n=44), 55–64 years (n=20), 65–74 years (n=18). Results. In the gouty patients, the physical health component summary score was lower (39.8±9.1; p < 0.00001) and the mental health component summary score (51.72±8.3) did not differ from that in the population. The greatest dif- ferences were revealed in 4 scales reflecting the physical health component. The gouty patients versus the controls were found to have significantly higher scores of physical functioning (46.1±10.03 and 51.75±9.71; p < 0.0001), role physical functioning (46.7±9.9 and 51.56±9.92; p < 0.0001), pain intensity (45.41±10.11 and 51.64±10.20; p < 0.0001), and general health condition (47.73±9.6 and 51.47±10.15; p < 0.0001, respectively). Of statistical signifi- cance were also differences in the scales of vital capacity (p = 0.0006) and social functioning (p = 0.020). In the male gouty patients, the mental health and role emotional functioning scores were similar to the population-based control ones. Comparative analysis revealed the above-mentioned similar differences in different age groups.
Conclusion. The physical health of the gouty patients is mainly poor and their mental health is poor to a lesser degree; their social adaptation is decreased.
About the Authors
M. V. Mukagova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
V. G. Barskova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
M. S. Eliseev
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
References
1. Насонова ВА, Барскова ВГ. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения тру- дового и жизненного прогноза больных. Научно-практиче- ская ревматология. 2004;44(1):5–7. [Nasonova VA, Barskova VG. Early diagnostics and gout treatment – scientifically reasonable requirement of improvement of the labor and vital forecast of patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;44(1):5–7. (In Russ.)]
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223. DOI: 10.1186/ar3199.
3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyper- uricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011 Oct;63(10):3136–41. DOI: 10.1002/art.30520.
4. Lu X, Li X, Zhao Y, et al. Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing. Int J Rheum Dis. 2013 Sep 30. DOI: 10.1111/1756-185X.12156.
5. Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–74.
6. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–12. DOI: 10.1136/ard.2010.128454.
7. Bruce SP, Fugit RV. Breaking the chain of gout: pharmacist strate- gies to improve patient outcomes in gout and hyperuricemia.
8. A case-based monograph focusing on gout and hyperuricemia for pharmacists. A continuing pharmacy education activity.
9. U.S. Pharmacist. 2010 Feb;(2):1–12.
10. Edwards NL, Sunday JS, Forsuthe A, et al. Work productivity loss due
11. to flares in patient with chronic gout refractory to conventional therapy.
12. J Med Econ 2011;14(1):10–5. DOI: 10.3111/13696998.2010.540874.
13. Kim KY, Schumacher HR, Hunsche E, et al. A literature review of
14. the epidemiology and treatment of acute gout. Clin Ther. 2003;(25):1593–617. DOI: http://dx.doi.org/10.1016/S0149- 2918(03)80158-3.
15. Елисеев МС, Мукагова МВ, Барскова ВГ. Качество жизни больных подагрой. Современная ревматология. 2011;(4):35–8. [Eliseyev MS, Mukagova MV, Barskova VG. Quality of life of patients with gout. Sovremennaya revmatologiya = Modern Rheumatology. 2011;(4):35–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2011-695.
16. Амирджанова ВН, Горячев ДВ, Коршунов НИ и др. Популяци- онные показатели качества жизни по опроснику SF-36 (результа-ты многоцентрового исследования качества жизни «МИРАЖ»). Научно-практическая ревматология. 2008;(1):36–48. [Amirdjanova VN, Goryachev DV, Korshunov NI, et al. Population indicators of quality of life on SF-36 questionnaire (results of multicen- ter research of quality of life «MIRAGE»). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;(1):36–48.
17. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2008-852. 12. Roddy E, Zhang W, Doherty M. Is gout associated with reduced
18. quality of life? A case-control study. Rheumatology (Oxford). 2007;46(9):1441–4. DOI: http://dx.doi.org/10.1093/rheumatol- ogy/kem150.
19. Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productiv- ity, and increased healthcare resource use: Results from a cross- sectional survey. Health Qual Life Outcomes. 2012;10:117. DOI: 10.1186/1477-7525-10-117.
20. Khanna D, Sarkin AJ, Khanna PP, et al. Minimally important dif- ferences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011;50(7):1331–6. DOI: 10.1093/rheumatology/ker023. Epub 2011 Mar 3.
21. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisa- tion in US veterans. Ann Rheum Dis. 2008;67(9):1310–6. DOI: 10.1136/ard.2007.081604.
22. Chandratre P, Roddy E, Clarson L, et al. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031–40. DOI: 10.1093/rheumatology/ket265.
23. Schumacher HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36(10):2342–5. DOI: 10.3899/jrheum.090370.
24. Singh J, Taylor WJ, Simon LS, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38(7):1452–7. DOI: 10.3899/jrheum.110271.
25. Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метабо- лического синдрома и сопутствующих заболеваний у боль- ных подагрой. Даннные многоцентрового исследования. На- учно-практическая ревматология. 2012;50(6):15–8.
26. [Barskova VG, Eliseyev MS, Denisov IS, et al. The rate of meta- bolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):15–8. (In Russ.). DOI: http://dx.doi.org/10.14412/1995-4484-2012-1287.
27. Scire CA, Manara M, Cimmino MA, et al.; KING Study Collaborators. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013 Aug 23;15(5):101. DOI: 10.1186/ar4281.
28. Becker MA, Schumacher HR, Benjamin KL, et al.; Gout Natural History Study Group, Sundy JS. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May;36(5):1041–8. DOI: 10.3899/jrheum.071229.
29. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582–6. DOI: 10.1093/rheumatology/kep047.
Review
For citations:
Mukagova M.V., Barskova V.G., Eliseev M.S. QUALITY OF LIFE OF MALE GOUTY PATIENTS: ARE THERE DIFFERENCES FROM THE POPULATION? RESULTS OF A COMPARATIVE STUDY. Rheumatology Science and Practice. 2014;52(3):300-303. (In Russ.) https://doi.org/10.14412/1995-4484-2014-300-303
Views:
934
Email this article 